Metagenomi Therapeutics, Inc. - Common Stock (NQ:MGX)

1.240 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EDT, Jul 17, 2026 Add to My Watchlist

Price and Volume

Volume	127,409
Open	1.250
Bid (Size)	1.220 (100)
Ask (Size)	1.290 (300)
Prev. Close	1.240
Today's Range	1.220 - 1.260
52wk Range	1.130 - 3.950
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Prolynx Names Simon Harnest as Chief Financial Officer and Amer Mirza, PhD, as Chief Scientific Officer as It Advances Multi-Program Obesity and Metabolic Disease Portfolio

July 15, 2026

Appointments strengthen financial and scientific leadership to help advance multiple ultra-long-acting incretin and non-incretin therapies toward the clinic

From ProLynx Inc.

Via GlobeNewswire

Metagenomi Therapeutics, Inc. to Present at the Jefferies Global Healthcare Conference

May 28, 2026

From Metagenomi Therapeutics, Inc.

Via GlobeNewswire

Performance

YTD	-25.7%	-25.7%
1 Month	+3.3%	+3.3%
3 Month	-19.0%	-19.0%
6 Month	-23.0%	-23.0%
1 Year	-37.7%	-37.7%

More News

Metagenomi Therapeutics Reports Business Updates and First Quarter 2026 Financial Results

May 11, 2026

From Metagenomi Therapeutics, Inc.

Via GlobeNewswire

Metagenomi Therapeutics, Inc. Announces Publication in Nature Structural & Molecular Biology Highlighting Proprietary Compact CRISPR Nuclease with Enhanced Genome Editing Efficiency

April 16, 2026

From Metagenomi Therapeutics, Inc.

Via GlobeNewswire

Metagenomi Therapeutics Reports Business Updates and Full Year 2025 Financial Results

March 05, 2026

From Metagenomi, Inc.

Via GlobeNewswire

Metagenomi Therapeutics, Inc. to Present at the 46th Annual TD Cowen Healthcare Conference

February 23, 2026

From Metagenomi, Inc.

Via GlobeNewswire

Metagenomi Announces Corporate Name Change to Metagenomi Therapeutics, Inc. and Highlights Recent Business Milestones and 2026 Corporate Outlook

January 12, 2026

From Metagenomi, Inc.

Via GlobeNewswire

Metagenomi to Present Preclinical Data Supporting New Collaboration Target of APOC3 with Ionis Pharmaceuticals at Upcoming Nature Conference

December 01, 2025

From Metagenomi, Inc.

Via GlobeNewswire

Metagenomi to Present at Jefferies Global Healthcare Conference in London

November 17, 2025

From Metagenomi, Inc.

Via GlobeNewswire

Metagenomi Prioritizes Hemophilia A Program, Lays Off 25% Workforce ↗

November 12, 2025

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

November 12, 2025

Via Benzinga

These stocks are moving in today's after hours session ↗

November 11, 2025

Via Chartmill

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

November 11, 2025

Via Benzinga

Metagenomi Reports Third Quarter 2025 Financial Results and Announces Strategic Pipeline Prioritization and Leadership Updates

November 11, 2025

From Metagenomi, Inc.

Via GlobeNewswire

Metagenomi Presents New Preclinical Data from MGX-001 Hemophilia A Program Supporting Advancement into Clinical Development

November 11, 2025

From Metagenomi, Inc.

Via GlobeNewswire

Metagenomi Inc (NASDAQ:MGX) Q2 2025 Earnings: Revenue Surpasses Estimates, Loss Narrower Than Expected ↗

August 12, 2025

Via Chartmill

Metagenomi Reports Business Updates and Second Quarter 2025 Financial Results

August 12, 2025

From Metagenomi, Inc.

Via GlobeNewswire

Metagenomi Appoints Laurence Reid, PhD to its Board of Directors

August 11, 2025

From Metagenomi, Inc.

Via GlobeNewswire

Which stocks are gapping on Wednesday? ↗

July 09, 2025

Via Chartmill

Sam Altman Says He 'Didn't Think' Elon Musk Would Abuse Government Power, Tesla CEO Hits Back With 'Scam Altman' Jibe ↗

June 20, 2025

Via Benzinga

Eli Lilly's $1.3 Billion Verve Deal Signals Confidence In Gene Editing Space: Analyst ↗

June 18, 2025

Via Benzinga

Demystifying Metagenomi: Insights From 4 Analyst Reviews ↗

May 15, 2025

Via Benzinga

Levi Strauss To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Thursday ↗

May 15, 2025

Via Benzinga

Metagenomi Presents Data Highlighting Advancements in Next-Generation Genome Editing Technologies at ASGCT Annual Meeting 2025

May 14, 2025

From Metagenomi, Inc.

Via GlobeNewswire

Metagenomi Reports Business Updates and First Quarter 2025 Financial Results

May 13, 2025

From Metagenomi, Inc.

Via GlobeNewswire

Frequently Asked Questions

Is Metagenomi Therapeutics, Inc. - Common Stock publicly traded?

Yes, Metagenomi Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Metagenomi Therapeutics, Inc. - Common Stock trade on?

Metagenomi Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Metagenomi Therapeutics, Inc. - Common Stock?

The ticker symbol for Metagenomi Therapeutics, Inc. - Common Stock is MGX on the Nasdaq Stock Market

What is the current price of Metagenomi Therapeutics, Inc. - Common Stock?

The current price of Metagenomi Therapeutics, Inc. - Common Stock is 1.240

When was Metagenomi Therapeutics, Inc. - Common Stock last traded?

The last trade of Metagenomi Therapeutics, Inc. - Common Stock was at 07/17/26 04:00 PM ET

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.